Distinguishing the economic costs associated with type 1 and type 2 diabetes - PubMed (original) (raw)
Distinguishing the economic costs associated with type 1 and type 2 diabetes
Timothy M Dall et al. Popul Health Manag. 2009 Apr.
Abstract
The objective was to estimate the economic costs of diagnosed type 1 (T1DM) and type 2 (T2DM) diabetes mellitus in the United States in 2007. Medical claims were analyzed to estimate the proportion of diagnosed diabetes cases and excess medical costs by diabetes type. Indirect costs associated with T1DM and T2DM were estimated by using findings from the literature on diagnosed diabetes, as well as differences in health per case of T1DM and T2DM. This study builds on the Cost of Diabetes Model developed for the American Diabetes Association to estimate the economic burden of diagnosed diabetes. T1DM accounts for an estimated 5.7% (1.0 million) of the 17.5 million people with diagnosed diabetes. Approximately 14.9billion(8.614.9 billion (8.6%) of the economic burden of diagnosed diabetes is associated with T1DM, including medical costs of 14.9billion(8.610.5 billion and indirect costs of 4.4billion.CostsassociatedwithT2DMare4.4 billion. Costs associated with T2DM are 4.4billion.CostsassociatedwithT2DMare159.5 billion, including medical costs of 105.7billionandindirectcostsof105.7 billion and indirect costs of 105.7billionandindirectcostsof53.8 billion. The economic burden per case of diabetes is greater for T1DM than for T2DM, and the difference increases with age. The prevalence of T2DM is significantly greater than the prevalence of T1DM, so T2DM is responsible for most of the economic burden of diabetes. Estimates for T1DM are sensitive to the criteria used to identify people with diabetes using claims data; estimates for T2DM are relatively stable. Improved coding of diabetes type in medical claims and identification of diabetes type in survey data could lead to more precise estimates of the economic burden by diabetes type.
Similar articles
- Healthcare resource utilization and cost among patients with type 1 diabetes in the United States.
Simeone JC, Shah S, Ganz ML, Sullivan S, Koralova A, LeGrand J, Bushman J. Simeone JC, et al. J Manag Care Spec Pharm. 2020 Nov;26(11):1399-1410. doi: 10.18553/jmcp.2020.26.11.1399. J Manag Care Spec Pharm. 2020. PMID: 33119443 Free PMC article. - Direct medical costs for complications among children and adults with diabetes in the US commercial payer setting.
Yeaw J, Halinan S, Hines D, Delozier A, Perez M, Boye M, Boye KS, Blanchette CM. Yeaw J, et al. Appl Health Econ Health Policy. 2014 Apr;12(2):219-30. doi: 10.1007/s40258-014-0086-9. Appl Health Econ Health Policy. 2014. PMID: 24573912 - Cost of hospital treatment of type 1 diabetes (T1DM) and type 2 diabetes (T2DM) compared to the non-diabetes population: a detailed economic evaluation.
Stedman M, Lunt M, Davies M, Livingston M, Duff C, Fryer A, Anderson SG, Gadsby R, Gibson M, Rayman G, Heald A. Stedman M, et al. BMJ Open. 2020 May 5;10(5):e033231. doi: 10.1136/bmjopen-2019-033231. BMJ Open. 2020. PMID: 32376746 Free PMC article. - Economic costs of diabetes in the U.S. In 2007.
American Diabetes Association. American Diabetes Association. Diabetes Care. 2008 Mar;31(3):596-615. doi: 10.2337/dc08-9017. Diabetes Care. 2008. PMID: 18308683 Review. - Economic Impact of Diabetes in Africa.
Mapa-Tassou C, Katte JC, Mba Maadjhou C, Mbanya JC. Mapa-Tassou C, et al. Curr Diab Rep. 2019 Jan 24;19(2):5. doi: 10.1007/s11892-019-1124-7. Curr Diab Rep. 2019. PMID: 30680578 Review.
Cited by
- Emetine Di-HCl Attenuates Type 1 Diabetes Mellitus in Mice.
Hudson LK, Dancho ME, Li J, Bruchfeld JB, Ragab AA, He MM, Bragg M, Lenaghan D, Quinn MD, Fritz JR, Tanzi MV, Silverman HA, Hanes WM, Levine YA, Pavlov VA, Olofsson PS, Roth J, Al-Abed Y, Andersson U, Tracey KJ, Chavan SS. Hudson LK, et al. Mol Med. 2016 Oct;22:585-596. doi: 10.2119/molmed.2016.00082. Epub 2016 Jun 10. Mol Med. 2016. PMID: 27341452 Free PMC article. - Multi-sensor fusion for enhanced contextual awareness of everyday activities with ubiquitous devices.
Guiry JJ, van de Ven P, Nelson J. Guiry JJ, et al. Sensors (Basel). 2014 Mar 21;14(3):5687-701. doi: 10.3390/s140305687. Sensors (Basel). 2014. PMID: 24662406 Free PMC article. - Global Impacts of Western Diet and Its Effects on Metabolism and Health: A Narrative Review.
Clemente-Suárez VJ, Beltrán-Velasco AI, Redondo-Flórez L, Martín-Rodríguez A, Tornero-Aguilera JF. Clemente-Suárez VJ, et al. Nutrients. 2023 Jun 14;15(12):2749. doi: 10.3390/nu15122749. Nutrients. 2023. PMID: 37375654 Free PMC article. Review. - Healthcare resource utilization and cost among patients with type 1 diabetes in the United States.
Simeone JC, Shah S, Ganz ML, Sullivan S, Koralova A, LeGrand J, Bushman J. Simeone JC, et al. J Manag Care Spec Pharm. 2020 Nov;26(11):1399-1410. doi: 10.18553/jmcp.2020.26.11.1399. J Manag Care Spec Pharm. 2020. PMID: 33119443 Free PMC article. - A randomized clinical trial aimed at preventing poor psychosocial and glycemic outcomes in teens with type 1 diabetes (T1D).
Weissberg-Benchell J, Rausch J, Iturralde E, Jedraszko A, Hood K. Weissberg-Benchell J, et al. Contemp Clin Trials. 2016 Jul;49:78-84. doi: 10.1016/j.cct.2016.05.006. Epub 2016 Jun 4. Contemp Clin Trials. 2016. PMID: 27267154 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical